Barrett esophagus: An update

Nature Reviews Gastroenterology and Hepatology

Volumn 7, Issue 7, 2010, Pages 369-378

  Badreddine, Rami J ^a   Wang, Kenneth K ^b  

^a Salem Gastroenterology Associates   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BONE MORPHOGENETIC PROTEIN 4; CELECOXIB; CYCLIN D1; GLUTATHIONE TRANSFERASE; GLYCOCHENODEOXYCHOLIC ACID; GLYCOCHOLIC ACID; GLYCODEOXYCHOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHOTOSENSITIZING AGENT; PLACEBO; PROTEIN P53; PROTON PUMP INHIBITOR; STAT3 PROTEIN; TAUROCHOLIC ACID; TRANSCRIPTION FACTOR CDX2; BMP4 PROTEIN, HUMAN; CDX2 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN;

ANTIREFLUX OPERATION; ARGON PLASMA COAGULATION; AUTOFLUORESCENCE IMAGING; BARRETT ESOPHAGUS; CANCER RISK; CANCER SCREENING; CHROMOENDOSCOPY; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFOCAL LASER MICROSCOPY; CRYOTHERAPY; DIAGNOSTIC PROCEDURE; ELECTROCOAGULATION; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC MUCOSAL RESECTION; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; GASTROESOPHAGEAL REFLUX; GENETIC POLYMORPHISM; HELICOBACTER PYLORI; HUMAN; INTESTINE METAPLASIA; MEDICAL RESEARCH; MEDICAL SOCIETY; MOLECULAR MECHANICS; NARROW BAND IMAGING; NEODYMIUM LASER; OBESITY; PATHOGENESIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; UNITED KINGDOM; CATHETER ABLATION; CELL TRANSFORMATION; EPITHELIUM; INTESTINE MUCOSA; PATHOLOGY; PHOTOCHEMOTHERAPY;

BARRETT ESOPHAGUS; BONE MORPHOGENETIC PROTEIN 4; CATHETER ABLATION; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIUM; HOMEODOMAIN PROTEINS; HUMANS; INTESTINAL MUCOSA; PHOTOCHEMOTHERAPY;

EID: 77955849502     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2010.78     Document Type: Review

References (118)

1. Wang, K. K. and Sampliner, R. E. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barretts esophagus. Am. J. Gastroenterol. 103, 788-797 (2008).
2. Playford, R. J. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barretts oesophagus. Gut 55, 442 (2006).
3. Kerkhof, M., Steyerberg, E. W., Kusters, J. G., Kuipers, E. J. and Siersema, P. D. Predicting presence of intestinal metaplasia and dysplasia in columnar-lined esophagus: a multivariate analysis. Endoscopy 39, 772-778 (2007).
4. van Baal, J. W. et al. A comparative analysis by SAGE of gene expression profiles of Barretts esophagus, normal squamous esophagus, and gastric cardia. Gastroenterology 129, 1274-1281 (2005).
5. Kelty, C. J., Gough, M. D., Van Wyk, Q., Stephenson, T. J. and Ackroyd, R. Barretts oesophagus: intestinal metaplasia is not essential for cancer risk. Scand. J. Gastroenterol. 42, 1271-1274 (2007).
6. Sharma, P. et al. The development and validation of an endoscopic grading system for Barretts esophagus: the Prague C and M criteria. Gastroenterology 131, 1392-1399 (2006).
7. Bytzer, P., Christensen, P. B., Damkier, P., Vinding, K. and Seersholm, N. Adenocarcinoma of the esophagus and Barretts esophagus: a population-based study. Am. J. Gastroenterol. 94, 86-91 (1999).
8. Harrison, R. et al. Detection of intestinal metaplasia in Barretts esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am. J. Gastroenterol. 102, 1154-1161 (2007).
9. Montgomery, E. et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum. Pathol. 32, 368-378 (2001).
10. Odze, R. D. Barrett esophagus: histology and pathology for the clinician. Nat. Rev. Gastroenterol. Hepatol. 6, 478-490 (2009).
11. Eisen, G. M., Sandler, R. S., Murray, S. and Gottfried, M. The relationship between gastroesophageal reflux disease and its complications with Barretts esophagus. Am. J. Gastroenterol. 92, 27-31 (1997).
12. Chiu, P. W. et al. Esophageal pH exposure and epithelial cell differentiation. Dis. Esophagus 22, 596-599 (2009).
13. Fletcher, J., Wirz, A., Henry, E. and McColl, K. E. Studies of acid exposure immediately above the gastro-oesophageal squamocolumnar junction: evidence of short segment reflux. Gut 53, 168-173 (2004).
14. Farre, R. et al. Critical role of stress in increased oesophageal mucosa permeability and dilated intercellular spaces. Gut 56, 1191-1197 (2007).
15. Jovov, B. et al. Claudin-18: a dominant tight junction protein in Barretts esophagus and likely contributor to its acid resistance. Am. J. Physiol. Gastrointest. Liver Physiol. 293, G1106-G1113 (2007).
16. Fletcher, J., Wirz, A., Young, J., Vallance, R. and McColl, K. E. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 121, 775-783 (2001).
17. Iijima, K. et al. Dietary nitrate generates potentially mutagenic concentrations of nitric oxide at the gastroesophageal junction. Gastroenterology 122, 1248-1257 (2002).
18. Spechler, S. J. Review article: what I do now to manage adenocarcinoma risk, and what I may be doing in 10 years time. Aliment. Pharmacol. Ther. 20 (Suppl. 5), 105-110 (2004).
19. Clemons, N. J., McColl, K. E. and Fitzgerald, R. C. Nitric oxide and acid induce double-strand DNA breaks in Barretts esophagus carcinogenesis via distinct mechanisms. Gastroenterology 133, 1198-1209 (2007).
20. Chak, A. et al. Familial aggregation of Barretts oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut 51, 323-328 (2002).
21. Gerson, L. B., Shetler, K. and Triadafilopoulos, G. Prevalence of Barretts esophagus in asymptomatic individuals. Gastroenterology 123, 461-467 (2002). (Pubitemid 34827190)
22. Romero, Y. et al. Barretts esophagus: prevalence in symptomatic relatives. Am. J. Gastroenterol. 97, 1127-1132 (2002).
23. Romero, Y. et al. Familial aggregation of gastroesophageal reflux in patients with Barretts esophagus and esophageal adenocarcinoma. Gastroenterology 113, 1449-1456 (1997).
24. Trudgill, N. J., Kapur, K. C. and Riley, S. A. Familial clustering of reflux symptoms. Am. J. Gastroenterol. 94, 1172-1178 (1999).
25. Izzo, J. G. et al. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J. Clin. Oncol. 25, 698-707 (2007).
26. Kala, Z., Dolina, J., Marek, F. and Izakovicova Holla, L. Polymorphisms of glutathione S-transferase M1, T1 and P1 in patients with reflux esophagitis and Barretts esophagus. J. Hum. Genet. 52, 527-534 (2007).
27. Murphy, S. J. et al. A population-based association study of SNPs of GSTP1, MnSOD, GPX2 and Barretts esophagus and esophageal adenocarcinoma. Carcinogenesis 28, 1323-1328 (2007).
28. Payne, C. M. et al. Mitochondrial perturbation attenuates bile acid-induced cytotoxicity. Cell Biol. Toxicol. 21, 215-231 (2005).
29. Bernstein, H., Bernstein, C., Payne, C. M., Dvorakova, K. and Garewal, H. Bile acids as carcinogens in human gastrointestinal cancers. Mutat. Res. 589, 47-65 (2005).
30. Bernstein, H. et al. Activation of the promoters of genes associated with DNA damage, oxidative stress, ER stress and protein malfolding by the bile salt, deoxycholate. Toxicol. Lett. 108, 37-46 (1999).
31. Dvorak, K. et al. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barretts oesophagus. Gut 56, 763-771 (2007).
32. Dvorak, K. et al. Expression of bile acid transporting proteins in Barretts esophagus and esophageal adenocarcinoma. Am. J. Gastroenterol. 104, 302-309 (2009).
33. Rokkas, T., Pistiolas, D., Sechopoulos, P., Robotis, I. and Margantinis, G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin. Gastroenterol. Hepatol. 5, 1413-1417 (2007).
34. Wang, C., Yuan, Y. and Hunt, R. H. Helicobacter pylori infection and Barretts esophagus: a systematic review and meta-analysis. Am. J. Gastroenterol. 104, 492-500 (2009).
35. Chow, W. H. et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res. 58, 588-590 (1998).
36. Wu, A. H. et al. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int. J. Cancer 103, 815-821 (2003).
37. Ye, W. et al. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J. Natl Cancer Inst. 96, 388-396 (2004).
38. Malfertheiner, P. et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56, 772-781 (2007). (Pubitemid 46854190)
39. Laine, L. and Sugg, J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am. J. Gastroenterol. 97, 2992-2997 (2002).
40. Malfertheiner, P. et al. Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease-results from a randomized trial programme. Aliment. Pharmacol. Ther. 16, 1431-1442 (2002).
41. McColl, K. E., Dickson, A., El-Nujumi, A., El-Omar, E. and Kelman, A. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. Am. J. Gastroenterol. 95, 101-105 (2000).
42. Kuipers, E. J. et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 53, 12-20 (2004).
43. Moayyedi, P. et al. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 121, 1120-1126 (2001).
44. Abrams, J. A. Obesity and Barretts oesophagus: more than just reflux. Gut 58, 1437-1438 (2009).
45. El-Serag, H. B., Kvapil, P., Hacken-Bitar, J. and Kramer, J. R. Abdominal obesity and the risk of Barretts esophagus. Am. J. Gastroenterol. 100, 2151-2156 (2005).
46. Kubo, A. and Corley, D. A. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 15, 872-878 (2006). (Pubitemid 43823511)
47. Lagergren, J., Bergstrom, R. and Nyren, O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann. Intern. Med. 130, 883-890 (1999).
48. Moayyedi, P. The epidemiology of obesity and gastrointestinal and other diseases: an overview. Dig. Dis. Sci. 53, 2293-2299 (2008).
49. Moayyedi, P. Barretts esophagus and obesity: the missing part of the puzzle. Am. J. Gastroenterol. 103, 301-303 (2008).
50. Seidel, D., Muangpaisan, W., Hiro, H., Mathew, A. and Lyratzopoulos, G. The association between body mass index and Barretts esophagus: a systematic review. Dis. Esophagus 22, 564-570 (2009).
51. Corley, D. A. et al. Abdominal obesity and body mass index as risk factors for Barretts esophagus. Gastroenterology 133, 34-41 (2007).
52. Edelstein, Z. R., Farrow, D. C., Bronner, M. P., Rosen, S. N. and Vaughan, T. L. Central adiposity and risk of Barretts esophagus. Gastroenterology 133, 403-411 (2007).
53. Kendall, B. J. et al. Leptin and the risk of Barretts oesophagus. Gut 57, 448-454 (2008).
54. Rubenstein, J. H. et al. Association of adiponectin multimers with Barretts oesophagus. Gut 58, 1583-1589 (2009).
55. Milano, F. et al. Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology 132, 2412-2421 (2007).
56. Sarosi, G. et al. Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barretts esophagus. Dis. Esophagus 21, 43-50 (2008).
57. Moons, L. M. et al. A pro-inflammatory genotype predisposes to Barretts esophagus. Carcinogenesis 29, 926-931 (2008).
58. Fitzgerald, R. C. et al. Inflammatory gradient in Barretts oesophagus: implications for disease complications. Gut 51, 316-322 (2002).
59. Fitzgerald, R. C. et al. Diversity in the oesophageal phenotypic response to gastrooesophageal reflux: immunological determinants. Gut 50, 451-459 (2002).
60. Buttar, N. S. et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barretts esophagus. Gastroenterology 122, 1101-1112 (2002).
61. Liu, T. et al. Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells. Carcinogenesis 28, 488-496 (2007).
62. Pera, M. et al. Duodenal-content reflux into the esophagus leads to expression of Cdx2 and Muc2 in areas of squamous epithelium in rats. J. Gastrointest. Surg. 11, 869-874 (2007).
63. Phillips, R. W., Frierson, H. F. Jr and Moskaluk, C. A. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am. J. Surg. Pathol. 27, 1442-1447 (2003).
64. Krishnadath, K. K. Novel findings in the pathogenesis of esophageal columnar metaplasia or Barretts esophagus. Curr. Opin. Gastroenterol. 23, 440-445 (2007).
65. Seery, J. P. Stem cells of the oesophageal epithelium. J. Cell Sci. 115, 1783-1789 (2002).
66. Dvorak, K. et al. Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to barretts esophagus. Clin. Cancer Res. 13, 5305-5313 (2007).
67. Kazumori, H., Ishihara, S. and Kinoshita, Y. Roles of caudal-related homeobox gene Cdx1 in oesophageal epithelial cells in Barretts epithelium development. Gut 58, 620-628 (2009).
68. Kazumori, H., Ishihara, S., Rumi, M. A., Kadowaki, Y. and Kinoshita, Y. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barretts epithelium. Gut 55, 16-25 (2006).
69. Chao, D. L. et al. Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barretts esophagus: a long-term prospective study. Clin. Cancer Res. 14, 6988-6995 (2008).
70. Lin, O. S. et al. Blinded comparison of esophageal capsule endoscopy versus conventional endoscopy for a diagnosis of Barretts esophagus in patients with chronic gastroesophageal reflux. Gastrointest. Endosc. 65, 577-583 (2007).
71. Galmiche, J. P. et al. Screening for esophagitis and Barretts esophagus with wireless esophageal capsule endoscopy: a multicenter prospective trial in patients with reflux symptoms. Am. J. Gastroenterol. 103, 538-545 (2008).
72. Cotruta, B., Gheorghe, C. and Bancila, I. Magnifying endoscopy with narrow-band imaging or confocal laser endomicroscopy for in vivo rapid diagnostic of Barretts esophagus. J. Gastrointestin. Liver Dis. 18, 258-259 (2009).
73. Curvers, W. et al. Chromoendoscopy and narrowband imaging compared with high-resolution magnification endoscopy in Barretts esophagus. Gastroenterology 134, 670-679 (2008).
74. Curvers, W. L. et al. Mucosal morphology in Barretts esophagus: interobserver agreement and role of narrow band imaging. Endoscopy 40, 799-805 (2008).
75. Fock, K. M., Teo, E. K., Ang, T. L., Tan, J. Y. and Law, N. M. The utility of narrow band imaging in improving the endoscopic diagnosis of gastroesophageal reflux disease. Clin. Gastroenterol. Hepatol. 7, 54-59 (2009).
76. Lee, M. M. and Enns, R. Narrow band imaging in gastroesophageal reflux disease and Barretts esophagus. Can. J. Gastroenterol. 23, 84-87 (2009).
77. Mannath, J., Subramanian, V., Hawkey, C. J. and Ragunath, K. Narrow band imaging for characterization of high grade dysplasia and specialized intestinal metaplasia in Barretts esophagus: a meta-analysis. Endoscopy 42, 351-359 (2010).
78. Sharma, P. et al. The utility of a novel narrow band imaging endoscopy system in patients with Barretts esophagus. Gastrointest. Endosc. 64, 167-175 (2006).
79. Singh, R. et al. Narrow-band imaging with magnification in Barretts esophagus: validation of a simplified grading system of mucosal morphology patterns against histology. Endoscopy 40, 457-463 (2008).
80. Suzuki, H. and Saito, Y. Autofluorescence and narrow-band imaging endoscopy for detecting early-staged cancer in Barretts esophagus: a case report. Jpn. J. Clin. Oncol. 38, 871 (2008).
81. Wolfsen, H. C. et al. Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barretts Esophagus. Gastroenterology 135, 24-31 (2008).
82. Sharma, P. et al. Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barretts oesophagus. Gut 52, 24-27 (2003).
83. Goetz, M., Hoffman, A., Galle, P. R., Neurath, M. F. and Kiesslich, R. Confocal laser endoscopy: new approach to the early diagnosis of tumors of the esophagus and stomach. Future Oncol. 2, 469-476 (2006).
84. Goetz, M. and Kiesslich, R. Confocal endomicroscopy: in vivo diagnosis of neoplastic lesions of the gastrointestinal tract. Anticancer Res. 28, 353-360 (2008).
85. Kiesslich, R. et al. Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology 127, 706-713 (2004).
86. Kiesslich, R. and Canto, M. I. Confocal laser endomicroscopy. Gastrointest. Endosc. Clin. N. Am. 19, 261-272 (2009).
87. Kiesslich, R., Goetz, M. and Neurath, M. F. Confocal laser endomicroscopy for gastrointestinal diseases. Gastrointest. Endosc. Clin. N. Am. 18, 451-466 (2008).
88. Kiesslich, R., Goetz, M., Vieth, M., Galle, P. R. and Neurath, M. F. Confocal laser endomicroscopy. Gastrointest. Endosc. Clin. N. Am. 15, 715-731 (2005).
89. Kiesslich, R., Goetz, M., Vieth, M., Galle, P. R. and Neurath, M. F. Technology insight: confocal laser endoscopy for in vivo diagnosis of colorectal cancer. Nat. Clin. Pract. Oncol. 4, 480-490 (2007).
90. Kiesslich, R. and Neurath, M. F. Endoscopic confocal imaging. Clin. Gastroenterol. Hepatol. 3, S58-S60 (2005).
91. Meining, A. et al. In vivo histopathology for detection of gastrointestinal neoplasia with a portable, confocal miniprobe: an examiner blinded analysis. Clin. Gastroenterol. Hepatol. 5, 1261-1267 (2007).
92. Polglase, A. L. et al. A fluorescence confocal endomicroscope for in vivo microscopy of the upper- and the lower-GI tract. Gastrointest. Endosc. 62, 686-695 (2005).
93. Borovicka, J. et al. Autofluorescence endoscopy in surveillance of Barretts esophagus: a multicenter randomized trial on diagnostic efficacy. Endoscopy 38, 867-872 (2006).
94. Curvers, W. L. et al. Endoscopic tri-modal imaging for detection of early neoplasia in Barretts oesophagus: a multi-centre feasibility study using high-resolution endoscopy, autofluorescence imaging and narrow band imaging incorporated in one endoscopy system. Gut 57, 167-172 (2008).
95. Curvers, W. L. et al. Identification of predictive factors for early neoplasia in Barretts esophagus after autofluorescence imaging: a stepwise multicenter structured assessment. Gastrointest. Endosc. 70, 9-17 (2009).
96. Falk, G. W. Autofluorescence endoscopy. Gastrointest. Endosc. Clin. N. Am. 19, 209-220 (2009).
97. Kara, M. A., Peters, F. P., Fockens, P., ten Kate, F. J. and Bergman, J. J. Endoscopic videoautofluorescence imaging followed by narrow band imaging for detecting early neoplasia in Barretts esophagus. Gastrointest. Endosc. 64, 176-185 (2006).
98. Kara, M. A. et al. Endoscopic video autofluorescence imaging may improve the detection of early neoplasia in patients with Barretts esophagus. Gastrointest. Endosc. 61, 679-685 (2005).
99. Fennerty, M. B. Does chemoprevention of Barretts esophagus using acid suppression and/or COX-2 inhibition prevent neoplastic progression? Rev. Gastroenterol. Disord. 2 (Suppl. 2), S30-S37 (2002).
100. Fennerty, M. B. Barretts-related esophageal cancer: has the final hurdle been cleared, now paving the way for human chemoprevention trials? Gastroenterology 122, 1172-1175 (2002).
101. Umansky, M. et al. Proton pump inhibitors reduce cell cycle abnormalities in Barretts esophagus. Oncogene 20, 7987-7991 (2001).
102. Bateman, D. N. et al. Mortality study of 18,000 patients treated with omeprazole. Gut 52, 942-946 (2003).
103. Farrow, D. C. et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev. 7, 97-102 (1998).
104. Funkhouser, E. M. and Sharp, G. B. Aspirin and reduced risk of esophageal carcinoma. Cancer 76, 1116-1119 (1995).
105. Thun, M. J., Namboodiri, M. M., Calle, E. E., Flanders, W. D. and Heath, C. W. Jr. Aspirin use and risk of fatal cancer. Cancer Res. 53, 1322-1327 (1993).
106. Morris, C. D., Armstrong, G. R., Bigley, G., Green, H. and Attwood, S. E. Cyclooxygenase-2 expression in the Barretts metaplasia- dysplasia- adenocarcinoma sequence. Am. J. Gastroenterol. 96, 990-996 (2001).
107. Heath, E. I. et al. Secondary chemoprevention of Barretts esophagus with celecoxib: results of a randomized trial. J. Natl Cancer Inst. 99, 545-557 (2007).
108. El-Serag, H. B. et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barretts esophagus. Am. J. Gastroenterol. 99, 1877-1883 (2004).
109. Ouatu-Lascar, R., Fitzgerald, R. C. and Triadafilopoulos, G. Differentiation and proliferation in Barretts esophagus and the effects of acid suppression. Gastroenterology 117, 327-335 (1999).
110. Feagins, L. A. et al. Acid has antiproliferative effects in nonneoplastic Barretts epithelial cells. Am. J. Gastroenterol. 102, 10-20 (2007).
111. Hillman, L. C., Chiragakis, L., Shadbolt, B., Kaye, G. L. and Clarke, A. C. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barretts oesophagus. Med. J. Aust. 180, 387-391 (2004).
112. Overholt, B. F. et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barretts high-grade dysplasia. Gastrointest. Endosc. 66, 460-468 (2007).
113. Prasad, G. A. et al. Predictors of stricture formation after photodynamic therapy for highgrade dysplasia in Barretts esophagus. Gastrointest. Endosc. 65, 60-66 (2007).
114. Wolfsen, H. C., Hemminger, L. L., Wallace, M. B. and Devault, K. R. Clinical experience of patients undergoing photodynamic therapy for Barretts dysplasia or cancer. Aliment. Pharmacol. Ther. 20, 1125-1131 (2004).
115. Prasad, G. A. et al. Significance of neoplastic involvement of margins obtained by endoscopic mucosal resection in Barretts esophagus. Am. J. Gastroenterol. 102, 2380-2386 (2007).
116. Shaheen, N. J. et al. Radiofrequency ablation in Barretts esophagus with dysplasia. N. Engl. J. Med. 360, 2277-2288 (2009).
117. Sharma, V. K. et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barretts esophagus: 1-year follow-up of 100 patients. Gastrointest. Endosc. 65, 185-195 (2007).
118. Fleischer, D. E. et al. Endoscopic ablation of Barretts esophagus: a multicenter study with 2.5-year follow-up. Gastrointest. Endosc. 68, 867-876 (2008).